Financial Performance - Total revenue for the first half of 2024 reached RMB 97.84 billion, a slight increase of 0.8% compared to RMB 97.06 billion in the same period of 2023[9]. - Operating profit for the industry segment was RMB 3.47 billion, reflecting a 3.0% increase year-on-year[9]. - Profit attributable to shareholders of the parent company was RMB 720.1 million, down from RMB 1.36 billion in the same period last year[6]. - The group's profit attributable to shareholders was RMB 720 million, a decrease of RMB 640 million compared to the same period in 2023, primarily due to one-time losses from the disposal of non-core assets[10]. - The total profit attributable to shareholders for the six months ended June 30, 2024, was RMB 720.1 million, a decrease of 47.0% from RMB 1,359.7 million in the same period of 2023[33]. - The net profit for the six months ended June 30, 2024, was RMB 2,502.7 million, a decrease of 45.3% from RMB 4,572.9 million in the same period of 2023[142]. Revenue Breakdown - The health segment's revenue composition included 63% from pharmaceutical products, 9% from medical devices and diagnostics, and 28% from health services and consumption[29]. - The affluent segment's revenue consisted of 68% from insurance, 14% from asset management, and 18% from investment management[29]. - The technology and manufacturing segment's revenue was composed of 60% from technology and manufacturing and 40% from resources and environment[29]. - The Health segment generated RMB 23,260.5 million, accounting for 23.6% of total revenue, a decrease of 2.4% from RMB 23,837.6 million in the previous year[31]. - The Wealth segment saw a revenue increase of 5.9%, reaching RMB 26,947.3 million, up from RMB 25,435.0 million in the prior year[31]. - The Asset Management segment reported a significant growth of 21.4%, with revenue rising to RMB 8,489.7 million from 6,992.6 million year-on-year[31]. Debt and Financial Ratios - The adjusted total debt to total capital ratio was 50.2%, continuing a downward trend since 2020[1]. - As of the reporting period, the group's adjusted total debt was RMB 210.7 billion, with a total debt-to-capital ratio of 50.2%, maintaining a downward trend since 2020[13]. - The average debt cost for the group was 5.8%, with a slight increase of 19 basis points compared to the end of 2023, benefiting from stable domestic bank borrowing costs[13]. - The total debt of Fosun International reached RMB 222.31 billion as of June 30, 2024, an increase from RMB 211.92 billion at the end of 2023[118]. - The debt-to-capital ratio was 51.5% as of June 30, 2024, up from 50.4% at the end of 2023, indicating a slight increase in leverage[125]. Assets and Liabilities - Total assets increased by 1.7% to RMB 821,888 million compared to the end of 2023[29]. - The total assets as of June 30, 2024, amounted to RMB 821,888,026 thousand, reflecting a 1.7% increase from RMB 808,387,589 thousand at the end of 2023[35]. - Total liabilities increased to RMB 612,662,935 thousand from RMB 599,812,751 thousand, reflecting a rise of approximately 2.8%[146]. - The company’s inventory increased to RMB 26,920,793 thousand from RMB 26,233,846 thousand, which is an increase of about 2.62%[145]. Strategic Initiatives - The company invested approximately RMB 3.5 billion in scientific innovation during the reporting period[2]. - The group plans to continue enhancing the FES system to respond swiftly to global market challenges and explore value increments through investment and entrepreneurship systems[25]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[38]. - The company is focusing on strategic acquisitions to enhance its portfolio and market position[38]. Market and Membership Growth - The group's consumer membership reached 35.86 million, with membership sales contribution increasing to 52.3%, up 1.6 percentage points year-on-year[20]. - The MyFidelidade APP registered users exceeded 1.6 million, accounting for over 15% of Portugal's total population, with digital channel sales growing by 16% year-on-year[22]. - The membership platform "复遊會" had over 6.9 million members, a growth of 12.6%, with revenue of RMB 172.7 million, remaining stable year-on-year[74]. ESG and Sustainability - Fosun's MSCI ESG rating was AA, making it the only comprehensive enterprise in Greater China with this rating[3]. - The group received recognition as one of the top 1% in the global Sustainable Development Yearbook (China Edition) 2024 and was awarded the title of "Best Progress Company in the Industry" for its ESG efforts[26]. Foreign Exchange and Financial Management - The group faced foreign exchange risks due to holding assets and liabilities denominated in foreign currencies, which could lead to potential exchange losses or gains affecting profits or net assets[136]. - The group has adopted appropriate hedging strategies to mitigate foreign exchange risks and does not engage in speculative trading[138]. - The company recognized a foreign exchange gain of RMB 784,427 thousand in 2024, compared to a loss in the previous year, indicating a significant improvement in foreign exchange management[185].

Financial Performance - Total revenue for the first half of 2024 reached RMB 97.84 billion, a slight increase of 0.8% compared to RMB 97.06 billion in the same period of 2023[3]. - The profit attributable to shareholders of the parent company was RMB 720.1 million, a decrease of RMB 640 million from RMB 1.36 billion in the same period of 2023, primarily due to one-time losses from the disposal of non-core assets[6]. - The group's operating profit for the reporting period was RMB 3.47 billion, benefiting from strong performance in Fosun Portugal Insurance, which saw a 3.0% increase compared to the same period in 2023[5]. - The group reported a basic earnings per share of RMB 0.09, down from RMB 0.17 in the same period of 2023[3]. - The group’s profit attributable to shareholders was RMB 720 million, a decrease of 47.0% compared to the same period in 2023[28]. - The group reported that approximately 80% of customer service interactions were handled by the chatbot Maria, enhancing operational efficiency[20]. - The group reported a net impairment loss of RMB 993,202 across various segments[147]. - The total profit for the period was RMB 2,502,725, with the health segment contributing RMB 1,667,444 to this figure[145]. Revenue Breakdown - The group's total revenue from the Happiness segment was RMB 43,172.1 million, a slight increase of 0.4% from RMB 43,001.6 million in the previous year[32]. - In the Health segment, pharmaceutical products, medical devices and diagnostics, and health services and consumer income accounted for 63%, 9%, and 28% of total revenue, respectively[29]. - The Wealth segment's insurance, asset management, and investment income represented 68%, 14%, and 18% of total revenue, respectively[29]. - The health sector reported revenue of RMB 23,260.5 million for the six months ended June 30, 2024, a decrease of 2.4% compared to RMB 23,837.6 million for the same period in 2023[39]. - The Wealth segment reported a profit of RMB 26.8 million, down 86.9% from RMB 204.7 million in the previous year[34]. - The insurance segment reported a revenue of RMB 18,457.6 million, a slight increase of 0.1% year-on-year, and a profit attributable to shareholders of RMB 1,174.9 million, up 56.5%[80]. Asset Management and Debt - The group's adjusted total debt reached RMB 210.7 billion, with a debt-to-capital ratio of 50.2%, maintaining a downward trend since 2020[10]. - Average debt cost for the group was 5.8%, with a slight increase of 19 basis points compared to the end of 2023[10]. - The group maintained a stable credit outlook with a BB- rating confirmed by S&P, reflecting improvements in its credit situation[8]. - As of June 30, 2024, total debt amounted to RMB 222,309.5 million, an increase from RMB 211,923.9 million as of December 31, 2023[117]. - The long-term debt ratio was 47.6% as of June 30, 2024, down from 55.0% as of December 31, 2023[117]. - Total liabilities reached RMB 612,662,935,000, up from RMB 599,812,751,000, indicating an increase of approximately 2.83%[128]. Investments and Innovations - The group invested approximately RMB 3.5 billion to enhance its technology and innovation capabilities during the reporting period[18]. - The group established a logistics investment fund in Japan with an initial fundraising target of USD 100 million, primarily from external investors[15]. - The group launched the F-i6000 fully automated chemiluminescence immunoassay analyzer, which has been approved for market[19]. - The group achieved approval for 9 indications of 4 innovative drugs/biosimilars, including the domestically approved lyophilized rabies vaccine in China[19]. - The group completed 53 FES tool certifications and trained 1,154 experts, enhancing operational capabilities across 68 subsidiaries[23]. Market Performance and Strategy - The group continues to focus on core industries and household consumption, mitigating some adverse effects from the macroeconomic environment[5]. - The group is committed to a "lean and healthy" strategy, focusing on enhancing competitiveness while providing high-quality products and services to global family customers[4]. - The group plans to continue deepening the FES system to respond swiftly to global market challenges and enhance competitive advantages[23]. - The group plans to sell its entire stake in HAL, with the transaction yet to be completed as of the announcement date[40]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[151]. Subsidiary Performance - The group's Club Med achieved a global revenue of RMB 8,894.4 million in the first half of 2024, a year-on-year increase of 10.3%[13]. - Fosun Pharma achieved operating revenue of RMB 20,383 million during the reporting period, with a year-on-year growth of approximately 5.32% excluding COVID-related products[41]. - Gland Pharma's consolidated revenue for the reporting period was USD 354 million, reflecting a 44% year-on-year growth[49]. - Fosun Health achieved operating revenue of RMB 2.96 billion, a year-on-year decrease of 5.8%[56]. - Yuyuan Holdings reported an operating income of RMB 27.57 billion, a slight increase year-on-year, but net profit attributable to shareholders fell by 48.5% to RMB 1.14 billion due to decreased investment income from asset disposals[64]. Customer Engagement and Digital Transformation - The number of consumer members reached 35.86 million, with member sales contribution increasing to 52.3%, up 1.6 percentage points year-on-year[17]. - The MyFidelidade APP registered over 1.6 million users, accounting for more than 15% of Portugal's total population, with digital sales channels growing by 16%[20]. - The membership platform "Fuyouhui" has over 6.902 million members, a growth of 12.6% year-on-year[73]. Corporate Social Responsibility - The group announced a donation of RMB 10 million worth of artemisinin-based anti-malarial drugs to Africa over the next three years[25]. - The group was recognized as one of the top 1% in the Standard Global "Sustainable Development Yearbook (China Edition) 2024" for its ESG efforts[24].

Financial Performance - In 2023, Fosun International achieved total revenue of RMB 198.2 billion, representing an 8.6% year-on-year growth[1]. - The operating profit from industrial operations reached RMB 4.9 billion, a year-on-year increase of 20.4% compared to 2022[1]. - The net profit attributable to shareholders was RMB 1.38 billion, recovering from a loss of RMB 831.8 million in 2022[9]. - The company's total revenue for 2023 reached RMB 198.2 billion, representing a year-on-year increase of 8.6%[11]. - Net profit attributable to shareholders was RMB 1.38 billion, an increase of RMB 2.21 billion compared to the previous year[11]. - The revenue from the four core subsidiaries contributed 72% to the overall income, with Fosun Tourism achieving a revenue of RMB 17.15 billion, up 24.5% year-on-year[11]. - The group’s profit attributable to equity holders reached RMB 1,379.1 million, a significant increase of 265.8% compared to the previous year[74]. - The insurance segment reported a profit of RMB 790.2 million, marking a 126.6% increase year-on-year[74]. Debt Management - As of the end of the reporting period, Fosun reduced interest-bearing debt by RMB 15 billion compared to the end of 2022, with a total debt to total capital ratio of 50.4%, down 2.9 percentage points[2]. - The company's interest-bearing debt was RMB 211.92 billion, a decrease of RMB 15 billion from the end of 2022, with a total debt to total capital ratio of 50.4%, down 2.9 percentage points from December 31, 2022[21]. - The average debt cost slightly increased by 89 basis points to 5.60% from 4.71% in 2022, while the total interest-bearing debt decreased by RMB 15 billion to RMB 211.9 billion[27]. - The group’s total debt to total capital ratio decreased by 2.9 percentage points to 50.4%[27]. - The company signed a RMB 12 billion syndicated loan agreement with eight domestic banks at the beginning of 2023, reflecting strong support for private enterprises[21]. Revenue Sources - Overseas revenue amounted to RMB 89.2 billion, a 6% year-on-year increase, accounting for 45% of total revenue[2]. - Fosun's health segment generated revenue of RMB 46.3 billion, while the happiness segment saw revenue rise to RMB 88.9 billion, up from RMB 70.7 billion in 2022[9]. - Fosun Portugal Insurance reported a gross premium income of EUR 5.207 billion and a net profit of EUR 180 million in 2023[16]. - The health segment generated revenue of RMB 46,314.4 million, a decrease of 3.5% compared to the previous year, while the happiness segment saw a revenue increase of 25.7% to RMB 88,946.4 million[72]. - The Happy segment reported a revenue of RMB 88,946.4 million, a 25.7% increase year-on-year, primarily due to rising gold prices and strong post-pandemic vacation demand[119]. Investment and Innovation - The company invested RMB 7.4 billion in technological innovation during the reporting period[4]. - The company invested a total of RMB 7.4 billion in scientific innovation throughout 2023, supporting the development of new technologies and products[17]. - The company is focusing on AI applications across over 80 product matrices, enhancing the quality of grassroots medical development and clinical technology innovation[20]. - The company is actively promoting consumption scene innovation, integrating technology with offline experiences to enhance customer engagement[20]. - The company aims to achieve carbon peak by 2028 and carbon neutrality by 2050, with the establishment of a carbon neutrality committee and the release of its first TCFD report in April 2023[43]. Market Expansion and Strategy - Fosun's global strategy has led to the establishment of a presence in over 35 countries and regions, enhancing its operational capabilities and market reach[14]. - The company plans to focus on light asset operations and actively invest in core industries to enhance its ecosystem capabilities and value in 2024[5]. - The company aims to expand its light asset operation capabilities, leveraging its operational strengths to seize opportunities in the current financing environment[20]. - The company is committed to building a super cultural and commercial complex exceeding 1 million square meters in Shanghai's core business area[20]. ESG and Social Responsibility - Fosun's MSCI ESG rating is AA, making it the only comprehensive enterprise in Greater China with this rating[4]. - The company actively promotes carbon neutrality and energy-saving measures, demonstrating commitment to environmental protection[21]. - The company encourages its subsidiaries to enhance ESG efforts, reflecting a commitment to sustainable development[23]. - The company provided over 2,000 emergency relief items valued at RMB 1 million to Turkey following the earthquake in February 2023[44]. Health Sector Developments - The CAR-T cell therapy product, Yikaida®, has treated hundreds of patients and received approval for a second-line indication in June 2023[17]. - Fosun Pharma focuses on innovative drug development in key disease areas such as oncology and central nervous system disorders, enhancing its product pipeline through diverse collaboration models[48]. - Fosun Health aims to provide comprehensive health management services through an integrated online and offline medical service platform, enhancing accessibility for users across major economic regions in China[52]. - Fosun Pharma's innovative drug pipeline includes 6 new drugs with 8 indications approved for market, alongside 29 generic drug varieties[92]. Tourism and Leisure - In 2023, the revenue of Club Med reached RMB 15.12 billion, an increase of 19.2% compared to 2022, and 118.3% of the 2019 level[20]. - Fosun Tourism's total revenue reached RMB 17,151.8 million in 2023, a year-on-year increase of 24.5%[127]. - Sanya Atlantis achieved a revenue of RMB 1.67 billion in 2023, a significant increase of 90.9% year-on-year, with an average occupancy rate of 81.9%[20]. - Club Med's revenue was RMB 15,122.5 million in 2023, growing approximately 19.2% year-on-year and reaching 118.3% of 2019 levels[128]. Manufacturing and Production - The smart manufacturing segment achieved revenue of RMB 12,755.6 million, a year-on-year increase of 23.2%, while profit attributable to shareholders decreased by 22.3% to RMB 934.1 million[168]. - Hainan Mining's revenue for the reporting period reached RMB 198,200.3 million, an increase of RMB 15,774.5 million or 8.6% year-on-year[71]. - Hainan Mining completed the acquisition of a 49% stake in Rock Oil for USD 163 million, making it a wholly-owned subsidiary[172]. Insurance Sector Performance - The total gross premium of Fosun Portugal Insurance reached EUR 5.207 billion, a slight increase of 1.7% year-on-year, with non-life insurance premiums growing by 10.5%[143]. - Dingrui Reinsurance reported gross premium income of USD 1.761 billion, down from USD 2.295 billion in 2022[146]. - The insurance segment reported a revenue of RMB 37,453.6 million, a decrease of 5.1% year-on-year, primarily due to the disposal of AmeriTrust[141].

Financial Performance - The company's total revenue for the year ended December 31, 2023, was RMB 198.2 billion, representing an 8.6% increase year-on-year[4]. - Net profit attributable to shareholders reached RMB 1.38 billion, an increase of RMB 2.21 billion compared to the previous year[4]. - The group's operating profit amounted to RMB 4.9 billion, representing a year-on-year increase of 20.4%[25]. - The group's profit attributable to shareholders reached RMB 1,379.1 million, a significant increase of 265.8% compared to a loss of RMB 831.8 million in the previous year[74]. - The total profit for the year ended December 31, 2023, was RMB 5,347,126 thousand, a significant increase from RMB 2,996,562 thousand in 2022, representing an increase of approximately 78.5%[172]. Revenue Contributions - The four core subsidiaries contributed 72% to the overall revenue growth, with Fosun Tourism achieving a revenue of RMB 17.15 billion, up 24.5% year-on-year[4]. - The revenue of the jewelry fashion group under Yuyuan Co. reached RMB 36.7 billion in 2023, representing an 11% year-on-year growth, outperforming the industry average[13]. - Club Med achieved a record revenue of RMB 15.12 billion in 2023, a 19.2% increase compared to 2022, and 118.3% of the 2019 level[14]. - The average occupancy rate of Atlantis Sanya reached 81.9% in 2023, with a significant year-on-year revenue growth of 90.9% to RMB 1.67 billion[14]. - Fosun Tourism's total revenue was RMB 17,151.8 million, a year-on-year increase of 24.5%, with a profit of RMB 307.2 million compared to a loss of RMB 544.9 million in 2022[118]. Debt and Financial Position - The company's total interest-bearing debt decreased by RMB 15 billion to RMB 211.92 billion by the end of 2023, with a debt-to-capital ratio of 50.4%, down 2.9 percentage points from the end of 2022[17]. - Cash and bank balances reached RMB 92.5 billion, indicating a strong financial position[27]. - The average debt cost slightly increased to 5.60%, up 89 basis points from 4.71% in 2022[26]. - The group's total debt to total capital ratio decreased by 2.9 percentage points to 50.4%[27]. - The group has achieved a cash inflow of approximately RMB 40 billion by the end of the reporting period[26]. Innovation and R&D - In 2023, the company invested a total of RMB 7.4 billion in scientific innovation, covering multiple industry sectors with over ten innovation centers[10]. - The company plans to strengthen its research and development investments to seize global development opportunities[68]. - The company is actively exploring cutting-edge technologies such as RNA and gene therapy to boost its innovation capacity[50]. - The health segment emphasizes innovation, internationalization, integration, and intelligence to enhance product and brand strength[49]. - R&D investment totaled RMB 5,937 million, an increase of 0.88% year-on-year, with R&D expenses at RMB 4,346 million, up 1.02%[83]. Market Expansion and Global Operations - Overseas revenue amounted to RMB 89.2 billion, accounting for 45% of total revenue, with a year-on-year growth of 6%[7]. - The company has successfully launched multiple innovative drugs in overseas markets, including the first Chinese independently developed monoclonal antibody approved in over 40 countries[7]. - The company’s subsidiary, Fosun Pharma, received approval for its innovative drug, Hansizhuang®, in Indonesia, marking the first Chinese PD-1 monoclonal antibody approved in Southeast Asia[31]. - Fosun Pharma is expanding its pharmaceutical product distribution in over 40 countries in Africa, with a local manufacturing facility under construction in Côte d'Ivoire[88]. - Gland Pharma has expanded its presence to over 60 countries, focusing on strategic acquisitions and partnerships for growth[53]. Sustainability and ESG - The group has been recognized with an MSCI ESG AA rating for three consecutive years, ranking in the top 6% globally in sustainability assessments[20]. - The company released its first TCFD report in April 2023, demonstrating its commitment to climate action and sustainable financing[45]. - The company committed to achieving carbon peak by 2028 and carbon neutrality by 2050, supporting the Paris Agreement's 1.5°C target[44]. - The company received an ESG rating of 11.7 from Sustainalytics, ranking fourth globally among insurance companies and second in Europe[133]. - The company’s MSCI ESG rating remains at AA, making it the only comprehensive enterprise in Greater China with this rating[47]. Strategic Focus and Business Segments - The company is focusing on core family consumption sectors and has exited non-core assets to strengthen its financial position[5]. - The company aims to create more quality products and services for one billion families globally through its strategic initiatives[6]. - The company aims to enhance its core business focus and improve operational capabilities while gradually exiting non-core industries[68]. - The Happy Sector targets family consumption needs and has built a global happiness ecosystem, with investments in various segments including jewelry, food, and tourism[55]. - The Wealth Sector leverages insurance as a core financial asset, creating a global asset management ecosystem to enhance the company's health, happiness, and intelligent manufacturing sectors[60]. Insurance and Financial Services - The insurance segment reported a revenue of RMB 37,453.6 million, a 5.1% year-over-year decline, but a profit of RMB 790.2 million, a significant increase of 126.6% compared to the previous year[130]. - Fosun Portugal Insurance's total gross premium for 2023 was €5.207 billion, a slight increase of 1.7%, with non-life insurance premiums growing by 10.5% to €2.902 billion[132]. - The international business of Fosun Portugal Insurance saw a 10.6% increase in total premiums, reaching €1,703 million, highlighting the advantages of its international diversification strategy[132]. - Dingrui Reinsurance recorded a net profit of USD 200 million in 2023, a significant recovery from a loss of USD 261 million in 2022, with net asset value increasing from USD 1.12 billion to USD 1.28 billion[137]. - Fosun P&C Life reported total premium income of RMB 4,346 million in 2023, a year-on-year increase of 77.45%, with new single premium growth in agent channels, postal agency channels, and professional agency channels at 23%, 161%, and 222% respectively[138]. Product Development and Launches - The company successfully launched 5 products (19 indications) in mainland China and 2 products in Europe, Australia, and Indonesia, with significant approvals for new indications of its core product Hanshuang®[90]. - Three new products were launched in new regions, including the Soprano Titanium™ platform in North America, Opus in international markets, and Alma Veil™ in North America, enhancing the product portfolio[99]. - The company launched a strategic new product "藏品•舍得 10 年" targeting the RMB 1,000 price segment, enhancing its market positioning[116]. - The company has established a multi-level health and elderly care service brand, Fosun Kangyang, which includes three major brands and focuses on elderly care, rehabilitation, and community health services[54]. - The company aims to enhance its integrated online and offline medical services and expand specialty service capabilities in key economic regions[104].

聚焦發展，穩健升級 2023年上半年，國際政治經濟環境依然複雜多變，國內經濟溫和復甦，面對紛繁複雜的宏觀環境，復星 加快聚焦家庭消費主賽道，專注發展核心優勢產業，整體業務穩健向上。報告期內，本集團實現總收入 人民幣970.6億元，同比增長10.9%；反映企業經營質量的關鍵指標一產業運營利潤達人民幣33.7億元， 同比增長5.5%，若剔除已處置企業（含未交割企業）利潤因素，則同口徑同比強勁提升66%；報告期內歸 屬於母公司股東之淨利潤為人民幣13.6億元。 與此同時，復星持續優化資金和資產結構，加大非戰略非核心資產處置，並積極開拓融資渠道，流動性 保持良好韌性。報告期內，本集團合併報表層面退出項目回籠現金超人民幣200億元；2023年1月，復星 高科成功在國內獲得8家銀行的人民幣120億元銀團貸款，體現了國內銀行對民營企業發展的堅定支持。 在公開市場融資渠道方面，復星高科於2023年1月和7月分別完成人民幣10億元超短期融資券發行。報告 期內，本集團成功跨越公開債務的到期牆，共兌付境內債券人民幣67.3億元及超過美元27億元的境外債 務。截至2023年6月30日止，本集團於一年內已無大額境外債券到期。信用狀況的 ...

Fosun International Limited (OTCPK:FOSUF) Q2 2023 Earnings Conference Call August 30, 2023 10:00 PM ET Company Participants Guo Guangchang - Chairman Wang Qunbin - Executive Director, Co-Chairman Chen Qiyu - Executive Director, Co-CEO Xu Xiaoliang - Executive Director, Co-CEO Gong Ping - Executive Director, Executive President, CFO Conference Call Participants Ronald Leung - Guotai Junan Securities Unidentified Company Representative Dear investors and analyst, both online and off-line, good morning. Welcom ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 中期業績公告 （未經審核） 截至 2023 年 6 月 30 日止六個月 財務摘要 截至6月30日止六個月 以人民幣百萬元列示 2023 2022 （重列*） 總收入 97,064.6 87,549.6 健康 23,837.6 23,366.6 快樂 43,001.6 32,065.4 富足 25,435.0 27,629.5 保險 18,442.4 20,547.0 資管 6,992.6 7,082.5 智造 5,460.2 5,127.0 內部抵銷 (669.8) (638.9) 歸屬於母公司股東之利潤/（虧損） 1,359.7 2,282.2 ...

Financial Performance - The profit attributable to shareholders for 2022 was RMB 538.7 million, a significant decrease from RMB 10,084.5 million in 2021[2][8]. - Total revenue for 2022 reached RMB 175,393.4 million, up from RMB 161,291.2 million in 2021, representing a growth of approximately 8.5%[8]. - The group achieved a total revenue of RMB 175.39 billion in 2022, representing an increase of 8.7% year-on-year[10]. - Profit attributable to shareholders of the parent company was RMB 540 million, a significant decrease of 94.7% year-on-year[11]. - The group's operating profit was RMB 7.1 billion, a decrease of 32.9% year-on-year due to the impact of recurring domestic pandemic[29]. - The profit attributable to shareholders was RMB 540 million, down from RMB 1.008 billion in the same period of 2021[29]. - The profit attributable to equity holders of the parent company in 2022 was RMB 538.7 million, down from RMB 10,084.5 million in 2021, representing a decline of approximately 94.67%[186]. - The basic earnings per share for 2022 was RMB 0.06, a significant drop from RMB 1.21 in 2021[186]. Revenue Segmentation - The health segment generated revenue of RMB 48,001.3 million, an increase from RMB 43,979.8 million in the previous year[8]. - The happiness segment reported revenue of RMB 70,739.5 million, compared to RMB 66,898.3 million in 2021, reflecting a growth of about 5.5%[8]. - Overseas revenue reached RMB 77.36 billion in 2022, accounting for 44.1% of total revenue, with a year-on-year growth of 14.3%[15]. - The wealth segment's revenue was RMB 47,722.4 million, reflecting a 9.2% increase year-on-year, with insurance and asset management contributing RMB 32,427.8 million and RMB 15,294.6 million respectively[60]. - The happiness segment's brand consumption and tourism culture revenue accounted for 80% and 20% of its total revenue, respectively[59]. - The wealth segment's insurance and asset management revenues accounted for 68% and 22% of its total revenue, respectively[59]. Investment and Innovation - The group invested RMB 10.4 billion in scientific innovation in 2022, marking a 17% increase year-on-year[5]. - R&D investment reached RMB 10.4 billion, a year-on-year increase of 17%[17]. - The company plans to continue increasing innovation investment and will focus on the quantity and quality of R&D inputs in subsidiary assessments[19]. - The company aims to leverage its global operations and technological innovation to drive sustainable development and fulfill its social responsibilities[58]. - The strategic business segments include new energy materials, electronic chemicals, and biotechnology, focusing on continuous technological innovation and R&D investment[57]. Debt and Financial Strategy - Total debt to total capital ratio was 53.2% as of December 31, 2022, maintaining stability, with cash and bank deposits reaching RMB 100.56 billion[20]. - The company emphasizes a strategy of reducing interest-bearing debt and improving credit ratings as part of its financial strategy[21]. - The total debt for 2022 was RMB 226,919.2 million, a decrease from RMB 237,119.5 million in 2021, with a total debt to total capital ratio of 53.2%[186]. - The interest coverage ratio for 2022 was 3.1 times, down from 4.4 times in 2021, due to a decrease in EBITDA from RMB 42,107.6 million in 2021 to RMB 32,016.9 million in 2022[181]. Market Expansion and Global Operations - The company is focusing on enhancing its global operations and innovation capabilities, with a presence in over 35 countries and regions[4]. - The company aims to deepen its industry operations and enhance vertical integration to create leading enterprises in its advantageous sectors[12]. - The company has signed contracts for non-strategic asset disposals exceeding RMB 40 billion since June 2022, recovering nearly RMB 30 billion in cash flow[3]. - The company secured a loan of up to RMB 12 billion from a consortium of banks, indicating strong confidence in its future growth[11]. ESG and Sustainability - The company aims to achieve carbon peak by 2028 and carbon neutrality by 2050, with an MSCI ESG rating of AA, the only comprehensive enterprise in Greater China with this rating[6]. - The group has achieved a MSCI ESG rating of AA, being the only comprehensive enterprise in Greater China with this rating[24]. - The company has established an ESG board committee and management committee to implement its ESG strategy effectively[39]. - The group plans to enhance its ESG standards through investments, including the acquisition of Bai Zhong Environment, to prepare for carbon peak and carbon neutrality in the steel industry[54]. Consumer Engagement and Digital Transformation - Digital membership increased by 50.8 million, a year-on-year growth of 27%, with over 133 products achieving over 100 million in sales, a 20% increase[22]. - The average occupancy rate of Atlantis Sanya reached 96.0% in the first two months of 2023, with other resorts also achieving over 90% occupancy[13]. - The company emphasizes the importance of consumer confidence in economic growth and aims to provide healthier and happier lifestyles for families globally[12]. - The company is committed to improving its ESG governance, with Yuyuan Group's MSCI ESG rating upgraded from BB to BBB[95]. Product Development and Healthcare - The first PD-1 monoclonal antibody for small cell lung cancer was approved, and the CAR-T cell therapy product has benefited nearly 300 patients[18]. - The group has developed a new oral COVID-19 drug, Azvudine, which has been included in national treatment guidelines and medical insurance[26]. - The health sector focuses on innovative drug development and medical devices, responding to the increasing demand for quality healthcare products and services[42]. - Fosun Pharma achieved revenue of RMB 43,811 million, representing a year-on-year growth of 12.73%, and net profit attributable to shareholders (excluding non-recurring items) increased by 18.37% to RMB 3,879 million[71]. Corporate Governance - The board has appointed at least one-third independent non-executive directors in compliance with listing rules[192]. - The company has mechanisms in place to ensure the independence of directors, including annual confirmations of independence and the ability to seek independent professional advice[193]. - The board encourages all directors to express independent opinions and constructive questions during meetings[193]. - The company has established governance policies and procedures, ensuring compliance with legal and regulatory requirements[199].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 年度業績公告 截至2022年12月31日止年度 財務摘要 截至 12 月 31 日止年度 以人民幣百萬元列示 2022 2021 (重列*) 收入 175,393.4 161,291.2 健康 48,001.3 43,979.8 快樂 70,739.5 66,898.3 富足 47,722.4 43,699.4 保險 32,427.8 32,149.3 資管 15,294.6 11,550.1 智造 10,355.6 7,736.9 內部抵銷 (1,425.4) (1,023.2) 歸屬於母公司股東之利潤/（虧損） 538.7 10,084.5 ...